Science

Our Therapeutic Approach

Microbion is pioneering innovative, site-specific delivery approaches for the prevention and treatment of infectious diseases, leveraging both anti-infective and anti-inflammatory mechanisms of action.

Our site-specific delivery methods—including topical, inhaled, and direct administration to deep tissues during surgery—enable higher therapeutic concentrations of pravibismane at the site of infection, potentially resulting in greater efficacy. By avoiding systemic administration, this approach reduces off-target effects and systemic toxicity, leading to a highly favorable safety profile. Additionally, site-specific delivery lowers the risk of developing antibiotic resistance, a problem strongly associated with systemic antibiotic use. Together, these advantages create a compelling therapeutic and commercial opportunity.

Supported by extensive preclinical studies and data from over 340 human subjects across six clinical trials, our lead compound, pravibismane, is anticipated to safely and effectively treat antibiotic-resistant infections—including those caused by MRSA, VRE, CRE, and other resistant bacteria—as well as pathogens implicated in respiratory infections. Pravibismane’s potent activity against antibiotic-resistant pathogens and their biofilms, and its ability to reduce excessive or chronic inflammation, offer a novel and potentially transformative strategy for disease treatment.